|
News for Healthier Living
First Patient Treated with Federally Approved Lyfgenia(tm) for the Curative Gene Therapy Treatment of Sickle Cell Disease Leaves Joseph M. Sanzari Children's Hospital at Hackensack University Medical
The completion of the patient's treatment for sickle cell is the second pediatric curative gene therapy treatment completed this year on the Hackensack University Medical Center campus. The Lyfgenia treatment comes on the heels of Joseph M. Sanzari's treatment of a young girl who underwent treatment for another inherited blood disorder. The patient was treated with beta thalassemia using Zynteglo, which was approved by the FDA for the treatment of the inherited blood disorder at the same time as Lyfgenia was approved for sickle cell.
June 6, 2025
June 14 2025June 13 2025June 12 2025June 11 2025June 10 2025June 9 2025June 8 2025June 7 2025June 6 2025June 5 2025June 4 2025June 3 2025June 2 2025June 1 2025
|
|
|
|
|